News >

MCL Researcher Highlights Future of CAR T-Cell Therapy, Other Approaches

Jason Harris
Published: Thursday, Jul 12, 2018

Dr. Michael Wang

Michael Wang, MD,
In the ongoing phase II ZUMA-2 trial, investigators hope that the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) can lead to a breakthrough in patients with mantle cell lymphoma (MCL) who no longer respond to treatment (NCT02601313).

“In ZUMA-2, we are aiming to overcome resistance cost in mantle cell lymphoma,” said lead author Michael Wang, MD. “[To overcome] cost by targeted therapies and immunotherapies and to overcome resistance with cell therapies.”

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x